|
|
|
51-200 employees
View all
|
|
pharmaceuticals
|
|
Hemmelrather Weg 201,Leverkusen,Nordrhein-Westfalen,DE
|
|
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin. Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (ticker symbol: B8F) and on the US NASDAQ (ticker symbol: BFRA).
|
Biofrontera Group Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}.{last} | [email protected] |
100%
|
The widely used Biofrontera Group email format is {f}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Biofrontera Group customer service number call here +49 (0) 214 876 32 0. To contact Biofrontera Group customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.